bortezomib
Selected indexed studies
- Bortezomib in cancer therapy: Mechanisms, side effects, and future proteasome inhibitors. (Life Sci, 2024) [PMID:39413903]
- Selinexor-Bortezomib-Dexamethasone: A Review in Previously Treated Multiple Myeloma. (Target Oncol, 2023) [PMID:36622630]
- Acquired Bortezomib Resistance in Multiple Myeloma: From Mechanisms to Strategy. (Curr Treat Options Oncol, 2024) [PMID:39432172]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Selinexor-Bortezomib-Dexamethasone: A Review in Previously Treated Multiple Myeloma. (2023) pubmed
- Bortezomib in cancer therapy: Mechanisms, side effects, and future proteasome inhibitors. (2024) pubmed
- Acquired Bortezomib Resistance in Multiple Myeloma: From Mechanisms to Strategy. (2024) pubmed
- Bortezomib-based consolidation or maintenance therapy for multiple myeloma: a meta-analysis. (2020) pubmed
- Bortezomib-loaded lipidic-nano drug delivery systems; formulation, therapeutic efficacy, and pharmacokinetics. (2021) pubmed
- Bortezomib in kidney transplantation. (2015) pubmed
- Clinical Pharmacokinetics and Pharmacodynamics of Bortezomib. (2019) pubmed
- Pathological Mechanisms of Bortezomib-Induced Peripheral Neuropathy. (2021) pubmed
- The safety of bortezomib for the treatment of multiple myeloma. (2018) pubmed
- Bortezomib - First Therapeutic Proteasome Inhibitor for Cancer Therapy: A Review of Patent Literature. (2020) pubmed